Eris Lifesciences Ltd · NSE:ERIS
Eris Lifesciences — Q2 FY20 Earnings Presentation
15 slides from Eris Lifesciences's earnings presentation, Nov 7, 2019
Slide 1: Exchange covering letter: Investor Presentation
Date: November 7, 2019 To To The Department of Corporate Services National Stock Exchange of India Limited BSE Limited Exchange Plaza Phiroze Jeejeebhoy Towers Bandra Kurla Complex Dalal Street Bandra (E) Mumbai- 400001 Mumbai-400051 Security Code: 540596 Symbol: ERIS SUBJECT: INVESTOR PRESENTATION
Slide 2: Eris Lifesciences Ltd Q2 FY20 Investor Presentation
ERIS LIFESCIENCES LTD Q2 FY 20 INVESTOR PRESENTATION 1
Slide 3: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and the underlying assumptions
Slide 4: What's New at Eris
WHAT’S NEW AT ERIS Our intense focus on Patient Care Initiatives provides Eris an unhindered mindspace and superior facetime with super specialist and specialist doctors 59,000 ABPMs 1,24,000 30,000 Holter on Calls Patients screened Eris Becomes The First Indian Pharma Company To Publish A Study Bas
Slide 5: Q2 FY20 – Business Highlights
Q2 FY 20 – BUSINESS HIGHLIGHTS • IPM regains growth as Acute therapies outperform Q2 FY 20 yoy GR • Eris Q2 FY 20 yoy gr is 9.4% as per AIOCD Total • Eris retains Strong Growth Momentum in Chronic and 11.5% 9.4% Sub Chronic segments (11.4 % yoy gr vs 10.6% for IPM) • Business retains focus in faster
Slide 6: H1 FY20 – Secondary Growth
H1 FY 20 – SECONDARY GROWTH H1 FY 20 yoy GR Total 11.0% 9.8% Eris IPM Chronic + Sub Chronic Therapies Acute Therapies 12.6% 9.8% 9.8% 2.5% Eris IPM Eris IPM Source: AIOCD Sep’19 5
Slide 7: Q2 FY20 – Prescriptions Ranking
Q2 FY 20 - PRESCRIPTIONS RANKING Prescription Ranking* 4 3 3 CARDIOLOGY DIABETOLOGY GASTRO 3 10 CONSULTING NEUROLOGY PHYSICIAN Source: SMSRC Aug’19 * Rx Rank in Represented Market (Rx Jul-Aug’19) 6
Slide 8: FY20 – The Path Ahead
FY 20 – The Path Ahead • Sharper and Stronger Brands in the Core portfolio post tail rationalisation maintain growth momentum • Rationalised portfolio growing at 12.6% yoy in Q2 20 and 13.3% in H1 20 • H2 20 – Planned Expansion/ launch of Cardio Metabolic division and Dermatology Business with ~300
Slide 9: Q2 FY20 – Financial Highlights
Q2 FY 20 – FINANCIAL HIGHLIGHTS Q2 FY 20 Financial Performance 7.6 % 9.1 % 8.4 % yoy growth in Sales yoy growth in EBITDA yoy growth in Net Profit • 12.6 % yoy growth in sales after adjusting for previous year’s FDC ban and tail rationalisation • YPM = 4.4 with Number of MRs as on 30 Sept 2019 – 2,1
Slide 10: Q2 FY20 and H1 FY20 – Income Statement
Q2 FY 20 and H1 FY 20 – INCOME STATEMENT Consolidated Q2 FY 20 Q2 FY 19 Q2 FY 20 yoy GR H1 FY 20 H1 FY 19 H1 FY 20 yoy GR INR millions Sale of Products 2,805 2,606 7.6% 5,523 5,076 8.8% Other Operating Income 43 36 19.8% 67 73 -7.6% Revenue from Operations 2,848 2,642 7.8% 5,591 5,149 8.6% Gross Pro
Slide 11: Q2 FY20 and H1 FY20 – Entity Wise Sales
Q2 FY 20 and H1 FY 20 – ENTITY WISE SALES Consolidated Q2 FY 20 Q2 FY 19 Q2 FY 20 yoy GR H1 FY 20 H1 FY 19 H1 FY 20 yoy GR Sale of products Q2 FY 20 H1 FY 20 INR millions Q2 FY 20 Q2 FY 19 H1 FY 20 H1 FY 19 INR millions yoy GR yoy GR Sale of Products 2,805 2,606 7.6% 5,523 5,076 8.8% Consolidated 2,
Slide 12: Q2 FY20 and H1 FY20 – Balance Sheet and Cash Flow
Q2 FY 20 and H1 FY 20 – BALANCE SHEET AND CASH FLOW as on as on as on INR million 30 Sep 19 31 Mar 19 30 Sep 18 Equity 13,239 11,688 10,447 Debt 4 1,764 2,765 13,243 13,453 13,212 Tangible Assets 951 561 590 Intangible Assets 7,020 7,072 7,129 Net Current Assets 2,638 2,186 1,982 Treasury 2,634 3,63
Slide 13: 10 Year Financial Highlight
10 YEAR FINANCIAL HIGHLIGHT 9,822 8,556 7,495 5,970 5,456 5,591 5,088 3,931 2,739 2,054 955 356 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 H120 INR million Operating Revenue Op. EBITDA PAT FY 2009 FY 2010 FY 2011 FY 2012 FY 2013 FY 2014 FY 2015 FY 2016 FY 2017 FY 2018 FY 2019 Strategic i
Slide 14: Shareholder Profile
SHAREHOLDER PROFILE Shareholding of Promoters and Top 15 Institutional Investors FPI Others As on As on As on 1.08% 30-Sep-2019 30-Jun-2019 31-Mar-2019 5.08% Sr no Name of Shareholder 451* 509* 645* DIIs, Promoters 56.23% 56.23% 56.10% 13.65% 1 Motilal Oswal Mutual Fund 3.87% 3.97% 3.97% 2 Aditya Bi
Slide 15: Thank You
THANK YOU ERIS LIFESCIENCES LTD KRUTI RAVAL INVESTOR RELATIONS kruti@erislifesciences.com 14